Mayne Pharma (MYX AU): Cosette's A$7.40/Share Scheme

• Mayne Pharma (MYX AU), a leader in dermatology and women’s health, has entered into a Scheme Implementation Deed with US-based pharmaceutical outfit, Cosette Pharmaceuticals.

• Cosette is offering A$7.40/share, a 37% premium to last close. Apart from Mayne's shareholder approval, the Offer requires FIRB signing off.

• The Offer also has the backing of Mayne's two largest shareholder, Viburnum and Bruce Mathieson, collectively holding 14.1%. Implementation is expected late May, early June 2025. This is done.